These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26468869)

  • 21. Diagnostic accuracy of serum brain derived neurotrophic factor concentration in antidepressant naïve patients with first major depression episode.
    Karlović D; Serretti A; Jevtović S; Vrkić N; Serić V; Peleš AM
    J Psychiatr Res; 2013 Feb; 47(2):162-7. PubMed ID: 23102630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of Interferon beta treatment on quality of life in multiple sclerosis patients.
    Simone IL; Ceccarelli A; Tortorella C; Bellacosa A; Pellegrini F; Plasmati I; De Caro MF; Lopez M; Girolamo F; Livrea P
    Health Qual Life Outcomes; 2006 Dec; 4():96. PubMed ID: 17163989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Experience in the treatment of multiple sclerosis with interferon beta in Galicia].
    Romero-López J; Seijo-Martínez M; Del Campo V; Amigo-Jorrín MC; Arias M; Cortés-Laíño JA; Dapena-Bolaño D; López-González FJ; Lorenzo-González JR; Marín-Sánchez M; Muñoz-García D; Ozaita-Arteche G; Prieto JM
    Rev Neurol; 2003 Dec 1-15; 37(11):1001-4. PubMed ID: 14669137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A longitudinal observation of brain-derived neurotrophic factor mRNA levels in patients with relapsing-remitting multiple sclerosis.
    Liguori M; Fera F; Patitucci A; Manna I; Condino F; Valentino P; Telarico P; Cerasa A; Gioia MC; di Palma G; Quattrone A
    Brain Res; 2009 Feb; 1256():123-8. PubMed ID: 19071096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data.
    Moccia M; Affinito G; Capacchione A; Lanzillo R; Carotenuto A; Montella E; Triassi M; Morra VB; Palladino R
    PLoS One; 2021; 16(9):e0258017. PubMed ID: 34587188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between levels of brain-derived neurotrophic factor and metabolic parameters in patients with type 2 diabetes mellitus.
    Boyuk B; Degirmencioglu S; Atalay H; Guzel S; Acar A; Celebi A; Ekizoglu I; Simsek C
    J Diabetes Res; 2014; 2014():978143. PubMed ID: 25587547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy).
    Moccia M; Loperto I; Lanzillo R; Capacchione A; Carotenuto A; Triassi M; Brescia Morra V; Palladino R
    BMC Health Serv Res; 2020 Aug; 20(1):797. PubMed ID: 32847587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
    Mezei Z; Bereczki D; Csiba L; Csépány T
    Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
    J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis.
    Cunningham A; Gottberg K; von Koch L; Hillert J
    Acta Neurol Scand; 2010 Mar; 121(3):154-60. PubMed ID: 20055771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study.
    Saiz A; Mora S; Blanco J;
    Neurologia; 2015 May; 30(4):214-22. PubMed ID: 24484756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up.
    Tur C; Montalban X; Tintoré M; Nos C; Río J; Aymerich FX; Brieva L; Téllez N; Perkal H; Comabella M; Galán I; Calle D; Sastre-Garriga J; Rovira A
    Arch Neurol; 2011 Nov; 68(11):1421-7. PubMed ID: 22084124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered serum content of brain-derived neurotrophic factor isoforms in multiple sclerosis.
    Tongiorgi E; Sartori A; Baj G; Bratina A; Di Cola F; Zorzon M; Pizzolato G
    J Neurol Sci; 2012 Sep; 320(1-2):161-5. PubMed ID: 22836016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
    Murray TJ
    Curr Med Res Opin; 2004 Jan; 20(1):25-30. PubMed ID: 14741068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
    Zwibel HL;
    Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
    Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brain-derived neurotrophic factor in generalized anxiety disorder: results from a duloxetine clinical trial.
    Ball S; Marangell LB; Lipsius S; Russell JM
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jun; 43():217-21. PubMed ID: 23313564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.